Jackson, A. et al. (2023) Outcomes at one year in women with peripartum cardiomyopathy: findings from the ESC EORP PPCM Registry. European Journal of Heart Failure, (doi: 10.1002/ejhf.3055) (Early Online Publication)
![[img]](https://eprints.gla.ac.uk/style/images/fileicons/text.png) |
Text
307955.pdf - Accepted Version Restricted to Repository staff only until 12 October 2024. 1MB |
Abstract
Aims: There are few prospective reports of 1-year outcomes for women with peripartum cardiomyopathy (PPCM). We report findings from the European Society of Cardiology EURObservational Research Programme PPCM Registry. Methods and results: The registry enrolled women from 51 countries from 2012–2018. Eligibility included: 1) a peripartum state, 2) signs or symptoms of heart failure, 3) LV ejection fraction ≤45%, 4) exclusion of alternative causes of heart failure. We report mortality, thromboembolism, stroke, re-hospitalization, LV recovery and remodelling at 1 year. Differences between regions were compared. One-year mortality data were available in 535 (71%) women and follow-up differed across regions. At 1 year, death from any cause occurred in 8.4% of women, with regional variation (Europe 4.9%, Africa 6.5%, Asia-Pacific 9.2%, Middle East 18.9%, p < 0.001). The frequencies of thromboembolism and stroke were 6.3% and 2.5%, respectively, and were similar across regions. A total of 14.0% of women had at least one re-hospitalization and 3.5% had recurrent re-hospitalizations (i.e. two or more). Overall, 66.1% of women had recovery of LV function (22% between 6 months and 1 year), with a mean LVEF increase from baseline of 21.2% [±13.6]). Recovery occurred most frequently in Asia-Pacific (77.5%) and least frequently in the Middle East (32.7%). There were significant regional differences in the use of heart failure pharmacotherapies. Conclusions: Approximately 1 in 12 women with PPCM had died by 1 year and thromboembolism and stroke occurred in 6.3% and 2.5%, respectively. Around 1 in 7 women had been re-hospitalized and, in 1 in 3, LV recovery had not occurred. PPCM is associated with substantial mortality and morbidity globally.
| Item Type: | Articles |
|---|---|
| Additional Information: | Funding: Since the start of EORP, the following companies have supported the whole research programme: Abbott Vascular Int. (2011–21), Amgen Cardiovascular (2009–18), AstraZeneca (2014–21), Bayer AG (2009–18), Boehringer Ingelheim (2009–19), Boston Scientific (2009–12), The Bristol Myers Squibb and Pfizer Alliance (2011–19), Daiichi Sankyo Europe GmbH (2011–20), The Alliance Daiichi Sankyo Europe GmbH and Eli Lilly and Company (2014–17), Edwards (2016–19), Gedeon Richter Plc. (2014–16), Menarini Int. Op. (2009–12), MSD-Merck & Co. (2011–14), Novartis Pharma AG (2014–20), ResMed (2014–16), Sanofi (2009–11), SERVIER (2009–21), and Vifor (2019–22). AMJ is supported by a British Heart Foundation Clinical Research Training Fellowship (FS/18/14/33330), MCP by a Centre of Excellence Research Grant BHF (grant number 18/6/34217), PvdM by the European Research Council (grant: ERC-2016-StG – 715732), KS by Servier: Institut La Conference Hippocrate. |
| Status: | Early Online Publication |
| Refereed: | Yes |
| Glasgow Author(s) Enlighten ID: | Jackson, Dr Alice and Petrie, Professor Mark |
| Authors: | Jackson, A., Bauersachs, J., Petrie, M. C., van der Meer, P., Laroche, C., Farhan, H. A., Frogoudaki, A., Ibrahim, B., Fouad, D. A., Damasceno, A., Karaye, K., Goland, S., Maggioni, A. P., Briton, O., and Sliwa, K. |
| College/School: | College of Medical Veterinary and Life Sciences > School of Cardiovascular & Metabolic Health |
| Journal Name: | European Journal of Heart Failure |
| Publisher: | Wiley |
| ISSN: | 1388-9842 |
| ISSN (Online): | 1879-0844 |
| Published Online: | 12 October 2023 |
University Staff: Request a correction | Enlighten Editors: Update this record
Funder and Project Information
Funder and Project Information